VEMON from Venomtech.com working with Charles River Labs. They even use it in cosmetics.

Our recent discovery of venoms that inhibit the binding of SARS CoV2 to the ACE2 receptor can now be tested in full.

Steve Trim, Founder and Chief Scientific Officer, Venomtech, commented: “This is a fantastic opportunity to deliver the next phase of growth for Venomtech. We have been working hard on refining our understanding of venom components and their application as tools. Now we’ll have the support and resources to put this knowledge into practice, on a global scale.

Professor Karol Sikora, a leading British Oncologist and Chairman of the Venomtech Board said: “This financing allows us to rapidly develop a whole new realm of drugs, from the venom of snakes, spiders and reptiles. Millions of years of evolution have resulted in an extremely potent and sophisticated pharmacology. Understanding the novel molecular mechanisms will almost certainly yield powerful new drugs for cancer, immune regulation and even neuropsychiatric syndromes.

https://venomtech.co.uk/industries/drug-discovery/